You are here

MODULATION THERAPEUTICS, INC.

Company Information
Address 2711 CENTERVILLE RD, STE 400
WILMINGTON, DE, 19808-1645

http://modulationtherapeutics.com/default.html

Information

DUNS: 968675244

# of Employees: 7


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Development of mitoNEET agonists for the treatment of stroke

    Amount: $258,700.00

    ABSTRACT Stroke is the fifth leading cause of death and the leading cause of disability in the United StatesThere remains a critical need for innovative therapeutic approaches that can successfully pr ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  2. Development of an a MC1R selective companion diagnostic imaging probe

    Amount: $248,155.00

    The melanocortinreceptorMC Ris over expressed on uveal and cutaneous melanoma cellsbut notin healthy normal tissuesWe have developed a proprietary ligandMTIthat binds to MC R inmelanoma cells with hig ...

    SBIRPhase I2018Department of Health and Human Services
  3. Novel SCD1 inhibitors for treatment of cancer

    Amount: $2,000,000.00

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of ...

    STTRPhase II2018Department of Health and Human Services National Institutes of Health
  4. Development of PEGylated MTI-101 for the treatment of relapsed Myeloma

    Amount: $1,929,583.00

    ABSTRACTModulation Therapeutics is developing a first in class cyclic peptide coined MTIfor the treatment of multiple myelomaThe company currently has a license for the parent molecule which has been ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  5. Osteopontin targeted therapy for primary CNS lymphoma

    Amount: $283,986.00

    Abstract Primary central nervous system lymphoma PCNSL is an aggressive brain tumor with a dire unmet therapeutic need It has an overall incidence of per person years and is regarded a ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  6. Development of PEGylated MTI for the treatment of relapsed Myeloma

    Amount: $242,056.00

    ABSTRACT Modulation Therapeutics is developing a first in class cyclic peptide coined MTI for the treatment of multiple myeloma The company currently has a license for the parent molecule which ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  7. TARGETED AC RADIOPHARMACEUTICAL FOR METASTATIC UVEAL MELANOMA

    Amount: $1,999,987.00

    Melanocortin receptor MC R is highly expressed on uveal and cutaneous melanoma cells and not on any tissues that are of concern for causing toxicity We developed a proprietary ligand MC RL that ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  8. Novel SCD1 inhibitors for treatment of cancer

    Amount: $279,000.00

    DESCRIPTION provided by applicant Metastatic clear cell renal cell carcinoma mccRCC is an incurable cancer with a year survival of less than for which novel therapeutic agents need to be d ...

    STTRPhase I2016Department of Health and Human Services
  9. IGF OT IGF SBIR TOPIC

    Amount: $299,336.00

    Not Available

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  10. Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.

    Amount: $244,801.00

    DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enh ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government